Oxidized low-density lipoprotein is cytotoxic to human monocyte-macrophages: protection with lipophilic antioxidants  by Marchant, Christine E. et al.
FEBS 15006 FEBS Letters 358 (1995) 175 178 
Oxidized low-density lipoprotein is cytotoxic to human 
monocyte-macrophages: protection with lipophilic antioxidants 
Christine E. Marchant*, Nadine S. Law, Carina van der Veen, Simon J. Hardwick, 
Keri L.H. Carpenter, Malcolm J. Mitchinson 
Division of Cellular Pathology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK 
Received 6 December 1994 
Abstract Human monocyte-macrophages were incubated for 24 
h with low-density Hpoprotein (LDL) which had been previously 
oxidized for varying periods up to 24 h with copper ions, in the 
presence or absence of DL-ot-tocopberol or probucol. The release 
of radioactivity from cells preloaded with tritiated adenine was 
used as an assay of toxicity. Toxicity of oxidized LDL increased 
with duration of copper oxidation and with increasing evidence 
of lipid oxidation, measured by assay of thiobarbituric acid-reac- 
tive substances and by gas chromatography. Oxidation and toxic- 
ity were inhibited by DL-a-tocopherol (200/tM) and probucol (50 
riM). 
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I. Introduction 
The foam cells of atherosclerotic lesions have been demon- 
strated to be macrophages, whose death has been reported to 
contribute to the lipid core of advanced lesions [1]. Although 
the cause of cell death is uncertain, it has been suggested that 
it may result from the production of oxidized lipids by the 
macrophages themselves [2]. Cell types found in the lesion, such 
as smooth muscle cells, endothelial cells and macrophages, 
have been shown to oxidize LDL in vitro [3-5]. It was also 
demonstrated some years ago that LDL prepared in the ab- 
sence of antioxidants was toxic for smooth muscle cells and 
endothelial cells [6] and that neutrophil or macrophage-oxi- 
dized LDL was toxic for fibroblasts [5]. More recently, oxidized 
LDL has been shown to be toxic for mouse peritoneal macro- 
phages in vitro [7] leading to apoptosis [8,9]. Native LDL was 
toxic to the macrophages only after a time-lag, thought to be 
due to oxidation of the LDL by the macrophages themselves 
[7]. 
Lipophilic antioxidants uch as probucol can protect LDL 
from oxidation both in vivo [10] and in vitro [11]. ~-Tocopherol 
(vitamin E), found naturally in LDL, protects LDL from oxida- 
tion when administered in vivo [12,13] or in vitro [14]. Popula- 
tion plasma ~-tocopherol levels have been found to correlate 
inversely with the incidence of ischaemic heart disease [15] and 
~z-tocopherol supplements appear to protect against coronary 
artery disease [16,17]. This suggests that protection of LDL by 
lipophilic antioxidants could be important in the prevention of 
atherosclerosis. 
No studies on the potential toxicity of oxidized LDL to 
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human macrophages have been reported. We have therefore 
investigated the toxicity to human monocyte-macrophages of 
LDL pre-oxidized with copper sulphate for varying periods in 
order to determine the extent of oxidation necessary for toxic- 
ity. We have also investigated the potential protection against 
LDL oxidation and toxicity by the addition of DL-a-tocopherol 
or probucol prior to oxidation. 
2. Materials and methods 
All biochemicals were from Sigma Chemical Co. (Poole, Dorset, UK) 
unless otherwise stated and were of the highest purity available. 
[8-3H]Adenine (24 Ci/mmol) was obtained from Amersham Radio- 
chemicals Ltd. (Aylesbury, Bucks, UK). 
Human monocyte-macrophages w re isolated from the blood of 
adult volunteers using a modification of a method described by 
Cathcart et al. [5]. 120 ml blood was obtained by venepuncture, EDTA 
(2.7 mM) added and centrifuged at 1,500 × g, the plasma removed and 
replaced with PBS. The resulting cell suspension (30 ml) was then 
layered on to 15 ml Lymphoprep (Nycomed AS, Oslo, Norway) and 
centrifuged at 600 × g for 30 min. Mixed mononuclear cells were re- 
moved from the interface, washed three times with PBS containing 
bovine serum albumin (4 mg/ml) and diluted to approximately 3 x 106 
cells/ml in Iscove's Modified Dulbecco's medium (Gibco Ltd., Paisley, 
UK). 1 ml of this suspension was added to each of the wells of Falcon 
24-well plates (Becton Dickinson, New Jersey, USA) which had been 
pre-coated with foetal calf serum (100/al). After incubation for 1 h, the 
nonadherent cells were washed off with PBS, leaving a monolayer of 
monocyte-macrophages which were incubated in Macrophage-SFM 
(Gibco Ltd.) for up to 48 h before use. The medium was then changed 
to RPMI 1640 with 10% lipoprotein deficient foetal calf serum, penicil- 
lin (63/ag/ml) and streptomycin (100/ag/ml). 
LDL was prepared from pooled human EDTA-plasma by the 
method of Havel et al. [18]. The LDL was stored at 4°C in 1 mM EDTA 
for up to 4 weeks before use. It was then dialysed against PBS to remove 
EDTA and diluted to 1 mg/ml in PBS. De-~-tocopherol or probucol 
were dissolved in ethanol and added to samples of LDL at 4/al/ml to 
give a final concentration f200/aM De-~-tocopherol or 50/aM probu- 
col. These concentrations had previously been shown to inhibit LDL 
oxidation for up to 6 h. Copper sulphate solution (final concentration 
5/aM) was added to the LDL and incubated at 37°C for 0, 1, 2, 4, 6 
or 24 h. Chelex 100 resin was used to remove excess copper ions. 
Samples to be added to cells were used immediately. Butylated hy- 
droxytoluene (200/aM) and EDTA (1 mM) were added to aliquots to 
be analysed. Samples for analysis by gas chromatography (GC), were 
stored under argon at -20°C, and samples for TBARS assay or gel 
electrophoresis were stored at 4°C. Viability of the cells was determined 
using the method of Reid et al. [19]. Briefly, 1/aCi of tritiated adenine 
was added to each well of cells and incubated for 1 h. Unincorporated 
adenine was removed by washing with PBS and the medium replaced 
with RPMI 1640 supplemented with 10% lipoprotein-deficient foetal 
calf serum. Test LDL (200/ag) was added to each well and the cells 
incubated for 24 h at 37°C. Medium was then removed; Triton X-100 
(1% v/v) lysates of cells, and the medium, were both counted (disinte- 
grations per minute) by liquid scintillation counting and the percentage 
release of radioactivity into the medium was calculated. 
Lipids were extracted from the samples and processed for GC as 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSD1 0014-5793(94)01393-4 
176 C.E. Marchant et al./FEBS Letters 358 (1995) 175-178 
described previously [20]. The procedure comprised addition of internal 
standards (n-heptadecanoic acid, coprostane and 5~-cholestane), Bligh 
and Dyer extraction, sodium borohydride reduction, saponification 
and derivatisation to methyl esters and trimethysilyl esters. Analysis of 
lipids using GC was performed as described by Carpenter et al. [21], 
except hat a 30 m DB-1 fused silica capillary column, 0.32 mm internal 
diameter, 0.1 #m thickness (J&W Scientific, Folsom, CA, USA) was 
used. 
A thiobarbituric a id reactive substances (TBARS) assay based on 
that described by Slater and Sawyer [22] was used to assess LDL 
oxidation. Each sample (50 #1 ) was diluted to 500/11 with de-ionised 
water. Trichloroacetic acid (250 #l: 40% w/v) and thiobarbituric a id 
(250 #1: 1.34% w/v) were added, mixed and incubated at 90 100°C for 
30 min. Absorbance at 532 nm was measured and the TBARS assessed 
as malondialdehyde (MDA) equivalents using a standard curve of 
1,1,3,3-tetramethoxypropane. 
Determination f electrophoretic mobility of samples was carried out 
by applying 5/A of each sample to Paragon 'LIPO' lipoprotein electro- 
phoresis gels (Beckman, Brea, CA, USA). Gels were run at 100 V for 
30 min, followed by fixing in a solution of ethanol (60%), deionised 
water (30%) and glacial acetic acid (10%), then drying and staining with 
Paragon 'LIPO' stain (Sudan Black B). 
3. Results and discussion 
The aims of the present study were to investigate the relation- 
ship between extent of oxidation of LDL and its cytotoxicity 
to human monocyte-macrophages, to assess possible protection 
with lipophilic antioxidants and to measure oxidized LDL com- 
ponents by gas chromatography, in an attempt to identify 
which oxidation products may be responsible for toxicity. 
Using the TBARS assay as a measure, LDL oxidation was 
dependent on the duration of incubation with copper ions (5 
#M), increasing over 24 h of incubation (Fig. 1). The progress 
of oxidation was rapid up to 4 h and thereafter increased more 
slowly. DL-~-tocopherol (200 #M) reduced the oxidation of 
LDL from 2-6 h, but at 24 h there was little inhibitory effect. 
In contrast, probucol (50 #M) conferred longer-lasting inhibi- 
tion, of about 50% at 24 h. A similar time-course of LDL 
oxidation and inhibition with lipophilic antioxidants was found 
using measurements of relative lectrophoretic mobility on aga- 
rose gels (data not shown). 
Analysis of the various oxidized LDL extracts by GC 
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Fig. 1. LDL oxidation: LDL (1 mg/ml) was incubated with copper 
sulphate (5 #M) either alone or with DL-~-tocopherol (200 /.tM) or 
probucol (50 #M) for up to 24 h at 37°C. TBARS results are expressed 
as equivalent nmol MDA/mg LDL protein and are from one experi- 
ment ypical of three. 
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Fig. 2. Toxicity of oxidized LDL: LDL (1 mg/ml) was oxidized with 
5#M CuSO4 for up to 24 h in the presence or absence of oL-~-tocophe- 
rol (200 #M) or probucol (50 pM). Cells were exposed to 200 #g/ml of 
this oxidized LDL for 24 h. Results are expressed as the mean percent- 
age release of radioactivity from cells pre-loaded with tritiated adenine. 
Results are from one experiment typical of three and are the mean + 
standard eviation of triplicate wells. Control cultures containing no 
LDL gave a mean percentage r lease of 23.2. 
revealed epletion of linoleate (18:2) and arachidonate (20:4), 
accompanied by production of 7fl-hydroxycholesterol (Table 
1). Arachidonate was depleted more rapidly, and was undetect- 
able at 24 h in the absence of exogenous antioxidants. 18:2 and 
20:4 fell steeply in the first 4 h of oxidation and thereafter 
continued to fall but at a slower rate. 7fl-hydroxycholesterol 
was undetectable up to 2 h oxidation, but from 4 h onwards its 
production increased with time. Probucol (50 #M) was effective 
in inhibiting both depletion of polyunsaturates and production 
of 7fl-hydroxycholesterol, but the protective ffect of DL-e- 
tocopherol (200 #M) appeared to be exhausted by 24 h. 
Previous studies on the time-course of formation of lipid 
oxidation products from LDL suggested that the initial prod- 
ucts, after depletion of antioxidants, are lipid hydroperoxides 
[23]. Using the TBARS assay as a general measure of LDL 
oxidation, we observed no significant lag phase (Fig. 1), but a 
1 h lag was observed in the depletion of 18:2 and 20:4 fatty 
acids (Table 1). 
LDL oxidized in the presence of copper sulphate (5/.tM) for 
up to 24 h produced striking toxicity in human monocyte- 
macrophages (Fig. 2), measured as release of radioactivity, 
after 24 h exposure to oxidized LDL, from cells pre-loaded with 
tritiated adenine. The toxicity of LDL oxidized in the absence 
of lipophilic antioxidants was near-maximal fter 4 h incuba- 
tiou. Thus it appears that even mild oxidation of LDL produces 
toxicity. 
The protection conferred by DL-Cc-tocopherol and probucol 
diminished when LDL oxidation times were prolonged. It was 
virtually total at LDL oxidation times up to and including 4 h 
(Fig. 2). With a 24 h LDL oxidation time, no significant protec- 
tion was conferred by oL-~-tocopherol, but probucol afforded 
better protection at this concentration, which was still total 
after 6 h and partially effective ven after 24 h of oxidation. The 
initial rates of LDL oxidation (Fig. 1) up to 2 h, measured as 
TBARS, were similar in the absence and presence of antioxi- 
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Fig. 3. Correlation of LDL oxidation and toxicity for three separate 
experiments: curve fits were calculated using SigmaPlot software, as 
were the r 2 values. The fitted curves were of the form y = a(1-e-b~), 
where the constants a and b took different values for each experiment. 
For Expt. 1, r 2= 0.966, for Expt. 2, r 2= 0.907, and for Expt. 3, 
r 2 = 0.938. y axis = percentage release ofradiolabel above control, i.e. 
percentage r lease for cells exposed to oxidized LDL minus percentage 
release for control cells exposed to native LDL. x axis = TBARS 
(expressed as equivalent nmoles MDA/mg LDL protein) values for 
oxidized LDL have had the small background TBARS values found for 
native LDL subtracted from them. 
dants. However over the same 2 h period probucol and De-a- 
tocopherol inhibited the oxidation of both linoleate (18:2) and 
arachidonate (20:4), measured by GC (Table 1) and inhibited 
the toxicity of these samples (Fig. 2). 
The toxicity of oxidized LDL is presumably due to oxidation 
products of some of its various components, which include lipid 
hydroperoxides, aldehydes, oxysterols, and perhaps other, un- 
known toxic components. The relationship ofduration of LDL 
oxidation to toxicity in the present study, together with analysis 
of oxidized LDL (by the TBA assay and by GC) give some 
possible clues to the nature of the toxic agents. 
LDL oxidized for 4-24 h shows production of 7fl-hy- 
droxycholesterol (Table 1), and the known cytotoxicity of this 
compound [24], like various other oxysterols [24,25], suggests 
that it may be a significant contributor to the toxicity of these 
oxidized LDLs, particularly 24 h oxidized LDL, in which the 
7fl-hydroxycholesterol level was highest in these experiments. 
This is in agreement with the results of Hughes et al. [24], who 
found that the toxicity of 24 h copper-oxidized LDL to smooth 
muscle cells was associated with the 7-oxysterol fraction. How- 
ever, in the 1 h and 2 h-oxidized LDLs, 7fl-hydroxycholesterol 
was negligible (Table 1), and so other oxidation products may 
be responsible for the toxicity of the LDLs in this early stage 
of oxidation. However, 7fl-hydroxycholesterol is found in 
human lesions [25,26] suggesting that the LDL in the lesion is 
oxidized. Therefore it may well be the more prolonged oxida- 
tion times which are more relevant to the developing lesion. 
Figs. 1 and 2 show that toxicity rises more steeply than 
TBARS for the first 4 h of oxidation, perhaps uggesting that 
a non-TBA-reactive substance might be responsible. However, 
the high degree of correlation of toxicity with the TBARS 
content of the oxidized LDLs (Fig. 3) suggests a link between 
MDA (or other TBA-positive substances) and toxicity. How- 
ever, the curvilinear shape of the relationship, rather than a 
straight line, perhaps hints that toxicity of MDA alone might 
not be the explanation. Alternatively it may be that the toxic 
response to MDA is curvilinear. Interestingly, Hessler et al. 
found that MDA toxicity to fibroblasts was insufficient to ac- 
count for the toxicity of a lightly-oxidized form of LDL [27]. 
Lipid hydroperoxides are also possible candidates as toxic 
agents. Their formation during copper oxidation of LDL, 
though not measured here, has been found to be maximal at 
around 4 h, with their levels typically falling appreciably by 24 
h, owing to decomposition [28], though there may be enough 
remaining to contribute to later toxicity. In the course of the 
TBA assay lipid peroxides are liable to decompose toMDA and 
other TBARS, the extent depending on the precise conditions 
of the TBA assay [29]. The steep fall in polyunsaturates (18:2 
and 20: 4 fatty acids) over the first four hours of LDL oxidation 
(Table 1) supports the role of lipid hydroperoxides in early 
toxicity. 
Kuzuya et al. [30] attributed the toxicity of copper oxidized 
Table 1 
Levels of linoleate (18:2) arachidonate (20:4) and 7,8 hydroxycholesterol (7f -OH) in LDL oxidized with 5/zM copper sulphate in the presence or
absence of DL-~-tocopherol (200/tM) or probucol (50/IM) in one experiment. 
Linoleate, arachidonate and 7B-hydroxycholesterol content (rag/rag LDL protein) 
Time LDL+ Cu LDL + Cu + et-tocoDherol 
18:2 20:4 7B-OH 18:2 20:4 713-OH 18:2 
Oh 128.6 10.0 0.0 127.9 11.2 0.0 100.8 
1 h 125.5 12.4 0.0 107.7 8.6 0.0 111.7 
2h 81.1 3.6 0.0 115.4 11.8 0.0 116.1 
4h  58.3 2.3 5.8 107.9 8.8 0.0 112.1 
6h 66.4 4.4 2.6 118.4 13.0 0.0 126.2 
24h 37.3 0.0 16.6 62.4 3.1 17.7 115.3 
20:4 713-OH 
7.2 0.0 
7.7 0.0 
10.3 0.0 
8.6  0.0 
16.4 0.6 
13.0 1.6 
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LDL to its content of lipid peroxides and the presence of tran- 
sition metals. The toxic effects reported in the present study 
were probably not due to the persistence of low concentrations 
of free copper ions, because the oxidized LDL was treated with 
Chelex resin to remove copper ions and because we have incu- 
bated monocytes with 5/.tM copper ions alone, without causing 
toxicity (data not shown). This would not, however, exclude a 
role in cytotoxicity of a copper-LDL complex in the cytotox- 
icity or a combined effect of lipid peroxides plus residual traces 
of copper ions. 
The results indicate that the oxidation of LDL results in 
toxicity for human monocyte-macrophages andalthough the 
exact mechanism is not yet clear, lipophilic antioxidants inhibit 
both the oxidation and the resulting toxicity. Since to judge 
from histological appearances the macrophage is the only cell- 
type which dies in the atherosclerotic lesion [1], this is clearly 
of potential relevance to the mechanism of progression of 
atherosclerosis and therefore requires further study. 
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